ArticleObstetrics and gynecology2018
Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
Article in Obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.Lancet (London, England) · 2021Trial
- Outcomes and Long-term Follow-up of Epithelial Ovarian Cancer: Experience from the Lead Cancer Center of Pakistan.Journal of cancer & allied specialties · 2026Article
- A comparison of the burden of cancers between 1990 and 2019 in Iran: A national and subnational study.PloS one · 2025Article
- Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer.Military Medical Research · 2024Review
- Sensitive and Cost-Effective Tools in the Detection of Ovarian Cancer Biomarkers.Analytical science advances · 2024Article
- A dual-center study: can ultrasound radiomics differentiate type I and type II epithelial ovarian cancer patients with normal CA125 levels?The British journal of radiology · 2024Article
- Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer.Oncology letters · 2024Article
- Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models.Molecular biology reports · 2024Article
- Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review.BMJ oncology · 2024Article
- Role of Vitamin K in Selected Malignant Neoplasms in Women.Nutrients · 2022Review
- The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019.BMC public health · 2022Article
- Subsequent Ultrasonographic Non-Visualization of the Ovaries Is Hastened in Women with Only One Ovary Visualized Initially.Healthcare (Basel, Switzerland) · 2022Article
- Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram.Diagnostics (Basel, Switzerland) · 2022Article
- Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type.Diagnostics (Basel, Switzerland) · 2022Article
- Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.International journal of molecular sciences · 2021Review
- Article
- Biomarkers and Strategies for Early Detection of Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding.Diagnostics (Basel, Switzerland) · 2020Review
- Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer.
methodsEligibility included all asymptomatic women 50 years of age or older and women 25 years of age or older with a documented family history of ovarian cancer. From 1987 to 2017, 46,101 women received annual ultrasound screening in a prospective cohort trial. Women with a persisting abnormal screen underwent tumor morphology indexing, serum biomarker analysis, and surgery.
resultsSeventy-one invasive epithelial ovarian cancers and 17 epithelial ovarian tumors of low malignant potential were detected. No women with a low malignant potential tumor experienced recurrent disease. Stage distribution for screen-detected invasive epithelial ovarian cancers was stage I-30 (42%), stage II-15 (21%), stage III-26 (37%), and stage IV-0 (0%). Follow-up varied from 9.2 months to 27 years (mean 7.9 years). Disease-specific survival at 5, 10, and 20 years for women with invasive epithelial ovarian cancer detected by screening was 86±4%, 68±7%, and 65±7%, respectively, vs 45±2%, 31±2%, and 19±3%, respectively, for unscreened women with clinically detected ovarian cancer from the same geographic area who were treated at the same institution by the same treatment protocols (P<.001). Twenty-seven percent of screen-detected malignancies were type I and 73% were type II. The disease-specific survival of women with type I and type II screen-detected tumors was significantly higher than that of women with clinically detected type I and type II tumors and was related directly to earlier stage at detection.
conclusionAnnual ultrasound screening of at-risk asymptomatic women was associated with lower stage at detection and increased 5-, 10-, and 20-year disease-specific survival of women with both type I and type II epithelial ovarian cancer. CLINICAL
trial registrationOnCore Clinical Trials Management System, NCI-2013-01954.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.